News

The initial phase-one study will combine Amgen’s Blincyto (blinatumomab) with Merck’s Keytruda (pembrolizumab) to treat patients with diffuse large B-cell lymphoma, the most common type of non-Hodgkin lymphoma.

Acorda executive director of device and program management Sean Plunkett said: "CVT-427 represents an innovative approach to acute treatment of migraines. Applying Acorda’s proprietary ARCUS technology, we have

"The current lack of effective therapies for high grade gliomas, such as glioblastoma and anaplastic astrocytoma, leaves doctors with few options for treating patients," said Tom Mikkelsen, M.D.,

The candidate is the fourth to be advanced from the company’s development pipeline in the last year, with the program reaching development stage under two years. Redx Pharma

Farletuzumab is a humanized monoclonal antibody (mAb) that binds to folate receptor alpha (FRA), a cell-surface protein highly expressed in ovarian carcinoma but largely absent from normal tissue.

The approval is conditional solely upon a minor change to the informed consent form that has already been submitted to the FDA. Full approval of the amendment is

Oliceridine is being developed as a potential replacement for currently approved intravenous opioid analgesics. In a recently completed Phase 2 study in postoperative pain, oliceridine matched the analgesic

The program has been initiated today and will be made available to eligible patients in the U.S. and selected European countries diagnosed with relapsed or refractory acute myeloid

The companies agreed to further develop Zymeworks’ Effector Function Enhancement and Control Technology (EFECT) platform by designing, engineering, and testing new engineered Fc domains with specific antibody-mediated immune